Jinsong Lu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/290128/publications.pdf

Version: 2024-02-01

52	877	430874	552781
papers	citations	18	26
		h-index	g-index

53	53	53	1331
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	LncRNA MIR205HG expression predicts efficacyÂof neoadjuvant chemotherapy for patients with locally advanced breast cancer. Genes and Diseases, 2022, 9, 837-840.	3.4	5
2	Raman Nanotagsâ€Guided Intraoperative Sentinel Lymph Nodes Precise Location with Minimal Invasion. Advanced Science, 2022, 9, e2102405.	11.2	15
3	Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different ‹scp›CYP2D6‹/scp› genotypes: A propensityâ€score matched cohort study. International Journal of Cancer, 2022, 150, 1664-1676.	5.1	4
4	Abstract P2-12-02: Efficacy, safety and survival of neoadjuvant chemotherapy with different estrogen deprivation stratified by menstrual status versus chemotherapy alone in locally advanced breast cancer (SHPD002)â€"â€" A randomized multicentre, open-label, phase 3 Triab. Cancer Research, 2022, 82, P2-12-02-P2-12-02.	0.9	0
5	Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study. Clinical Cancer Research, 2022, 28, 3677-3685.	7.0	14
6	Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients. Frontiers in Oncology, 2021, 11, 604319.	2.8	10
7	Predictive value of lncRNA LOC100505851 in breast cancer in the neoadjuvant setting. Gland Surgery, 2021, 10, 1899-1909.	1.1	0
8	LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication. Journal of Experimental and Clinical Cancer Research, 2021, 40, 205.	8.6	20
9	Association of Neo-Family History Score with pathological complete response, safety, and survival outcomes in patients with breast cancer receiving neoadjuvant platinum-based chemotherapy: An exploratory analysis of two prospective trials. EClinicalMedicine, 2021, 38, 101031.	7.1	2
10	Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy. EBioMedicine, 2021, 71, 103560.	6.1	62
11	HIF1Î± Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 729965.	3.7	5
12	CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells. Nature Communications, 2021, 12, 5764.	12.8	38
13	Ultrasound-Guided Breast Biopsy: Improved Accuracy of 10-G Cable-Free Elite Compared With 14-G CCNB. Journal of Surgical Research, 2020, 247, 172-179.	1.6	5
14	Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). Cancer, 2020, 126, 3867-3882.	4.1	15
15	Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094088.	3.2	3
16	SHP-2-Mediated Upregulation of ZEB1 Is Important for PDGF-B-Induced Cell Proliferation and Metastatic Phenotype in Triple Negative Breast Cancer. Frontiers in Oncology, 2020, 10, 1230.	2.8	6
17	TIMELESS regulates sphingolipid metabolism and tumor cell growth through Sp1/ACER2/S1P axis in ER-positive breast cancer. Cell Death and Disease, 2020, 11, 892.	6.3	26
18	The impact of EGFR gene polymorphisms on the response and toxicity derived from neoadjuvant chemotherapy for breast cancer. Gland Surgery, 2020, 9, 925-935.	1.1	2

#	Article	IF	Citations
19	Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy. Frontiers in Oncology, 2020, 10, 631.	2.8	17
20	Upregulation of microRNAâ€'1 inhibits proliferation and metastasis of breast cancer. Molecular Medicine Reports, 2020, 22, 454-464.	2.4	21
21	The Predictive Value of Pre-therapeutic Serum Gamma-glutamyl transferase in Efficacy and Adverse Reactions to Neoadjuvant Chemotherapy among Breast Cancer Patients. Journal of Breast Cancer, 2020, 23, 509.	1.9	3
22	Programmed death-ligand 1 single nucleotide polymorphism affects breast cancer chemosensitivity and adverse events in the neoadjuvant setting. International Journal of Biological Markers, 2020, 35, 38-49.	1.8	1
23	Added value of mean and entropy of apparent diffusion coefficient values for evaluating histologic phenotypes of invasive ductal breast cancer with MR imaging. European Radiology, 2019, 29, 1425-1434.	4.5	31
24	Effects of serum from breast cancer surgery patients receiving perioperative dexmedetomidine on breast cancer cell malignancy: A prospective randomized controlled trial. Cancer Medicine, 2019, 8, 7603-7612.	2.8	18
25	Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer. BMC Cancer, 2019, 19, 877.	2.6	30
26	Elevated expression of Gab1 promotes breast cancer metastasis by dissociating the PAR complex. Journal of Experimental and Clinical Cancer Research, 2019, 38, 27.	8.6	18
27	Early breast cancer patients benefit more from longer course chemotherapy: a matched-pair analysis. Future Oncology, 2019, 15, 1781-1789.	2.4	1
28	Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting. Cancer Biology and Therapy, 2019, 20, 941-947.	3.4	15
29	Predictive and prognostic value of ZEB1 protein expression in breast cancer patients with neoadjuvant chemotherapy. Cancer Cell International, 2019, 19, 78.	4.1	10
30	Novel lymphocyte to red blood cell ratio (LRR), neutrophil to red blood cell ratio (NRR), monocyte to red blood cell ratio (MRR) as predictive and prognostic biomarkers for locally advanced breast cancer. Gland Surgery, 2019, 8, 627-635.	1.1	6
31	Predictive and prognostic value of prognostic nutritional index for locally advanced breast cancer. Gland Surgery, 2019, 8, 618-626.	1.1	17
32	DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC. Cancer Letters, 2019, 442, 242-251.	7.2	44
33	Identification and integrated analysis of key differentially expressed circular RNAs in ER-positive subtype breast cancer. Epigenomics, 2019, 11, 297-321.	2.1	25
34	Polymorphisms in microRNA let-7 binding sites of the HIF1AN and CLDN12 genes can predict pathologic complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer. Annals of Translational Medicine, 2019, 7, 138-138.	1.7	7
35	Single nucleotide polymorphisms of let-7-related genes increase susceptibility to breast cancer. American Journal of Translational Research (discontinued), 2019, 11, 1748-1759.	0.0	7
36	The ubiquitin-specific protease USP8 deubiquitinates and stabilizes Cx43. Journal of Biological Chemistry, 2018, 293, 8275-8284.	3.4	23

#	Article	IF	Citations
37	A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer. Breast Cancer: Targets and Therapy, 2018, Volume 10, 201-206.	1.8	5
38	Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting. OncoTargets and Therapy, 2018, Volume 11, 801-808.	2.0	21
39	Downregulated circulating microRNAs after surgery: potential noninvasive biomarkers for diagnosis and prognosis of early breast cancer. Cell Death Discovery, 2018, 4, 21.	4.7	28
40	HIC1 deletion promotes breast cancer progression by activating tumor cell/fibroblast crosstalk. Journal of Clinical Investigation, 2018, 128, 5235-5250.	8.2	65
41	Advances in treatment of metastatic breast cancer with bone metastasis. Chinese Clinical Oncology, 2018, 7, 31-31.	1.2	5
42	Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet Oncology, The, 2017, 18, 371-383.	10.7	43
43	Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study. Oncotarget, 2017, 8, 79305-79314.	1.8	26
44	Expression profile analysis of long noncoding RNA in ER-positive subtype breast cancer using microarray technique and bioinformatics. Cancer Management and Research, 2017, Volume 9, 891-901.	1.9	26
45	Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials. OncoTargets and Therapy, 2017, Volume 10, 3155-3168.	2.0	4
46	Single-nucleotide polymorphism in microRNA-binding site of SULF1 target gene as a protective factor against the susceptibility to breast cancer: a case-control study. OncoTargets and Therapy, 2016, 9, 2749.	2.0	7
47	A multicenter, cross-sectional research of the adherence to endocrine therapy with selective estrogen receptor modulators (SERMs) in premenopausal women in China.. Journal of Clinical Oncology, 2016, 34, e12025-e12025.	1.6	1
48	CXCL16/CXCR6 chemokine signaling mediates breast cancer progression by pERK1/2-dependent mechanisms. Oncotarget, 2015, 6, 14165-14178.	1.8	77
49	Clinical significance of locoregional and systemic treatment in operable high-risk breast cancer patients with more than four positive axillary lymph nodes. OncoTargets and Therapy, 2015, 8, 2665.	2.0	2
50	Prognostic effect of menstrual cycle on timing of surgery in premenopausal breast cancer patients. American Journal of Surgery, 2015, 210, 506-511.	1.8	3
51	National consensus in China on diagnosis and treatment of patients with advanced breast cancer. Annals of Translational Medicine, 2015, 3, 242.	1.7	14
52	For or against Adjuvant Trastuzumab for pT1a-bN0M0 Breast Cancer Patients with HER2-Positive Tumors: A Meta-Analysis of Published Literatures. PLoS ONE, 2014, 9, e83646.	2.5	24